STCube

STCube FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of STCube (052020.KQ) as of Oct 24, 2026 is 94.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 111.73 % — a change of -15.00% (lower).

FCF Conversion

94.98 %

YoY

-15.00%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of STCube is 2025 94.98 % . FCF Conversion Rate (FCF/EBITDA) of STCube was 2024 111.73 % . It decreases by -15.00% lower compared to the previous year.

The STCube FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
59.77 KRW
Jan 1, 2019
11.03 KRW
Jan 1, 2020
65.67 KRW
Jan 1, 2021
79.89 KRW
Jan 1, 2022
86.28 KRW
Jan 1, 2023
101.63 KRW
Jan 1, 2024
111.73 KRW
Jan 1, 2025
94.98 KRW
The STCube FCF Conversion history
YEARFCF ConversionYoY
94.98 %-15.00%
111.73 %+9.94%
101.63 %+17.80%
86.28 %+7.99%
79.89 %+21.66%
65.67 %+495.54%
11.03 %-81.55%
59.77 %-18.77%
73.58 %+654.03%
9.76 %-92.86%
136.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

FCF Conversion Rate (FCF/EBITDA) of STCube is 94.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of STCube changed from 111.73 % to 94.98 %, representing a -15.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) STCube since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — STCube

All Key Metrics — STCube